Sort by:

Kaiser Y, Garris CS, Marinari E, Kim HS, Oh J, Pedard M, Halabi EA, Choi M, Parvanian S, Kohler R, Migliorini D, Weissleder R

Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
Nat Biomed Eng. 2025;:ePub - PMID: 41125869 - DOI: 10.1038/s41551-025-01533-2

Kim HS, Simpson GG, Carrothers J, Nguyen YTM, Kohler R, Hong S, Cha S, Kim DH, Garris CS, Weissleder R

A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy.
ACS Nano. 2025;19(41):36451-36464 - PMID: 41061756 - DOI: 10.1021/acsnano.5c10081

Parvanian S, Ge X, Garris CS

Recent developments in myeloid immune modulation in cancer therapy.
Trends Cancer. 2025;11(4):365-375 - PMID: 39794212 - DOI: 10.1016/j.trecan.2024.12.003

Qin T, Mattox AK, Campbell JS, Park JC, Shin KY, Li S, Sadow PM, Faquin WC, Micevic G, Daniels AJ, Haddad R, Garris CS, Pittet MJ, Mempel TR, ONeill A, Sartor MA, Pai SI

Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
J Clin Invest. 2025;135(6):ePub - PMID: 40091844 - PMCID: PMC11910227 - DOI: 10.1172/JCI181671

Oh J*, Hoelzl J*, Carlson JCT, Bill R, Peterson HM, Faquin WC, Pittet MJ, Pai SI, Weissleder R

Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer
Cell Rep Med. 2025;6(5):102100 - PMID: 40311615 - PMCID: PMC12147904 - DOI: 10.1016/j.xcrm.2025.102100
5 CSV